Welcome to our dedicated page for Argenx Se news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on Argenx Se stock.
argenx SE reports developments as a global immunology company developing and commercializing antibody-based medicines for severe autoimmune diseases. Its updates center on VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), including approved use in adult generalized myasthenia gravis and clinical and regulatory work across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Recurring announcements also cover product sales, business updates, presentations of neuromuscular data, and pipeline progress for candidates such as empasiprubart, a monoclonal antibody targeting complement factor C2, and adimanebart. Governance items include annual general meeting results, board appointments, and leadership transitions for the Euronext- and Nasdaq-listed foreign issuer.
argenx (NASDAQ:ARGX) announced management participation in two June 2026 investor conferences. The team will present at the William Blair 46th Annual Growth Stock Conference on June 3, 2026 at 12:40 p.m. CT in Chicago and join a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026 at 4:00 p.m. ET in Miami.
A live webcast and 30-day replay will be available in the Investors section of the argenx website.
MindWalk Holdings (NASDAQ: HYFT) reported that over 20 drug candidates in partner pipelines originated from its antibody discovery work, with 10 programs now in active Phase 1–3 clinical trials across oncology, immunology, neurology, and infectious disease.
The company highlighted its HYFT® and LensAI™ biological intelligence infrastructure, built on a Knowledge Graph indexing 660 million biological patterns and 25 billion relationships, and a record of 400+ peer-reviewed publications and patents supporting collaborations with firms such as Annexon, argenx, Xencor, Cullinan Oncology, and others.
argenx (NASDAQ:ARGX) announced U.S. FDA approval expanding VYVGART and VYVGART Hytrulo to treat all adult gMG serotypes (anti-AChR, anti-MuSK, anti-LRP4 and triple seronegative) based on Phase 3 ADAPT SERON data, including a statistically significant primary endpoint (p=0.0068) and a 3.35‑point mean MG‑ADL improvement at week 4. The approval cites rapid, sustained symptom improvements and a tolerability profile consistent with prior data, and broadens prescribing to adults regardless of serotype. Access support is available via the My VYVGART Path program.
argenx (NASDAQ:ARGX) reported Q1 2026 results and a business update: $1.3B product net sales (+63% YoY), operating profit of $394M, profit for the period of $366M (+116% YoY), and cash and current financial assets of $4.9B as of March 31, 2026.
Key near-term catalysts include a PDUFA date for seronegative gMG on May 10, 2026, multiple upcoming topline readouts in 2026–2027, and pipeline progression toward 10 clinical candidates by end of 2026.
argenx (Euronext & Nasdaq: ARGX) announced that CEO Karen Massey will present at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026 at 10:40 a.m. PT.
A live webcast will be available at argenx.com/investors, with a replay accessible on the company website for approximately 30 days after the presentation.
argenx (Euronext & Nasdaq: ARGX) announced board changes following its Annual General Meeting on May 6, 2026. Karen Massey was appointed Chief Executive Officer and executive director for a four-year term, while co-founder Tim Van Hauwermeiren becomes Chairperson and non-executive director.
Shareholder turnout was 90.9% and all agenda items passed, including a shareholder authorization to issue shares or subscription rights up to 10% of outstanding capital for 18 months.
argenx (Euronext & Nasdaq: ARGX) will report its first quarter 2026 financial results and host a business update on May 7, 2026 at 2:30 PM CET / 8:30 AM ET. The company will hold a conference call and audio webcast for investors and analysts.
A live webcast is available at the Investors section of argenx.com/investors and a replay will remain accessible for approximately one year. Dial-in access numbers and access code 3810049 are provided; participants are asked to dial in 15 minutes early.
argenx (Nasdaq: ARGX) presented new VYVGART data at AAN 2026 showing expanded efficacy across myasthenia gravis (MG) subtypes and CIDP. ADAPT OCULUS met its primary endpoint (p=0.012) in ocular MG; sBLAs for oMG and broader gMG populations have regulatory submissions in progress, including a priority review target action date of May 10, 2026.
ADHERE post hoc and real-world data support early benefit and IVIg-to-Hytrulo switching in CIDP, and pediatric/adolescent ADAPT Jr results show durable symptom gains.
argenx (Euronext & Nasdaq: ARGX) announced its Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol.
Agenda items include adoption of the 2025 annual accounts, advisory vote on the 2025 remuneration report, discharge of directors, share issuance authorization and several board appointments and reappointments. Documents and e-voting information are available on the argenx website and via ABN AMRO e-voting; shareholders are encouraged to vote by proxy. For copies contact legal@argenx.com.
argenx (NASDAQ: ARGX) will present clinical and real-world data for VYVGART and pipeline candidates at the 2026 AAN Annual Meeting (April 18–22, 2026) in Chicago.
Highlights include positive Phase 3 ADAPT OCULUS results in ocular myasthenia gravis, ADAPT SERON data showing efficacy in AChR‑Ab–negative gMG subtypes, CIDP biomarker and ADHERE analyses, and ARGX‑119 Phase 1b safety and functional improvements.